High-level Genomic Sequencing Expenditure
In order to have a high-level and initial estimation of genomic sequencing expenditure, based on current (2022) and future (2050) cancer incidence, I have decided to explore a very basic scenario. Europe and North America are aggregated here as regions where some adoption of sequencing is already underway.
This approach assumes one sample per case, and explores a range of uptake levels, defined here as the proportion of newly diagnosed cancer cases that would undergo genomic sequencing. Different cost scenarios are tested, ranging from €200 to €1000 per sample. The analysis reflects the use of targeted panel sequencing, which is currently the most common approach in oncology for identifying actionable mutations.
